DCZ0415- CAS 2242470-43-3
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients.
DCZ0415 (10, 20 μM; 72 hours) shows a significant decrease in colony formation, indicating it inhibits cell proliferation.
DCZ0415 (1.25-40 μM; 72 hours) induces a significant dose-dependent decrease of viability in
DCZ0415 (10, 20 μM; 24-72 hours) shows a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death.
DCZ0415 (10, 20 μM; 24 hours) induces a significant accumulation in G0/G1 MM cells.
DCZ0415 (10 μM; 48 hours) decreases the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells.
DCZ0415 has IC50s of 1.0–10 μM in CalcuSyn in MM cell lines.
DCZ0415 exerts cytotoxic effects by inhibiting DNA 288 synthesis in MM cells.
DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice.
Catalog Number: I017385
CAS Number: 2242470-43-3
Molecular Formula: C₂₃H₂₀N₂O₂
* For research use only. Not for human or veterinary use.